During Tuesday’s trading session, shares of a BSE-listed pharmaceutical company engaged in the trading and distribution of raw materials as a supply chain management are in focus, after the company announced securing an export deal worth Rs. 182.7 crores, particularly in the UK and Europe.
With a market capitalisation of Rs. 146.8 crores, the shares of Remedium Lifecare Limited were trading in the red at Rs. 1.64 on BSE, down by nearly 2 percent, as against its previous closing price of Rs. 1.67. The stock has delivered negative returns of around 88 percent in one year, but gained by over 3 percent in the last one month.
What’s the News
According to the latest regulatory filings on the BSE, Remedium Lifecare Limited has secured a Rs. 182.7 crores multi-year export contract with a leading pharmaceutical distributor.
The company is focusing on bolstering its Contract Development and Manufacturing Organization (CDMO) services and research & development (R&D) capabilities. This initiative is part of the company’s broader plan to strengthen its global presence, particularly in the UK and Europe.
Previous Updates
8th May: Remlife Global PTE Limited, a Singapore-based subsidiary of Remedium Lifecare, announced a partnership with JiyaYu Lifesciences PTE Ltd., a green chemistry technology platform company.
This collaboration will focus on replacing animal-origin raw materials in the manufacturing of APIs and advanced intermediates through proprietary fermentation and biocatalyst-based alternatives.
JiyaYu Lifesciences has, in turn, partnered with a UK-based R&D technology platform specialising in the development of fermentation and biocatalyst-based alternatives to animal-origin pharmaceutical inputs. Through this collaboration, JiyaYu gains access to cutting-edge innovations that it will transfer to Remlife Global as fully scalable technologies.
Financial Performance
Remedium Lifecare reported a decline in its revenue from operations, showing a year-on-year fall of around 98 percent from Rs. 1,834 crores in Q3 FY24 to Rs. 38 crores in Q3 FY25. Similarly, its net profit decreased during the same period from Rs. 46 crores to Rs. 0.8 crores, representing a decline of around 98 percent YoY.
About the Company
Remedium Lifecare Limited is a pharmaceutical company aligned across two business verticals: Products and Services. The Products business comprises trading and sale of Active Pharmaceutical Ingredients (APIs) and Intermediates to innovator and generic pharmaceutical players in both Domestic and International markets, including the regulated markets
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
